Mon, November 1, 2010
[ Mon, Nov 01st 2010 ] - Market Wire
00 p.m. Pacific Time
Fri, October 29, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
November 4, 2010
Thu, October 28, 2010
Wed, October 27, 2010
[ Wed, Oct 27th 2010 ] - Market Wire
Complete Edition Now Available
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
Fri, October 22, 2010
[ Fri, Oct 22nd 2010 ] - Market Wire
Financial Statement 09/10
Thu, October 21, 2010
[ Thu, Oct 21st 2010 ] - Market Wire
EA adquiere Chillingo
[ Thu, Oct 21st 2010 ] - Market Wire
EA bernimmt Chillingo
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ] - Market Wire
ASYS,BTN,NM,SORL,WYN
Tue, October 19, 2010
Mon, October 18, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ] - Market Wire
00 p.m. PST (5:00 p.m. EST)
[ Fri, Oct 15th 2010 ] - Market Wire
NOK,RIMM,AAPL,GOOG,MOT
Thu, October 14, 2010

Tikcro Technologies Announces 2010 Annual General Meeting


//science-technology.news-articles.net/content/2 .. ogies-announces-2010-annual-general-meeting.html
Published in Science and Technology on Monday, October 25th 2010 at 5:10 GMT by Market Wire   Print publication without navigation


TEL AVIV, Israel--([ BUSINESS WIRE ])--Tikcro Technologies Ltd. (OTCBB: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on November 30, 2010 at 3:00 p.m. Israel time, at the Company's offices, 126 Yigal Allon Street, Tel Aviv, Israel.

The agenda of the meeting is as follows:

(1) reelection of Eric Paneth and Izhak Tamir to the Board of Directors;

(2) reappointment of Kost Forer, Gabbay and Kasierer, a member of Ernst & Young, as independent auditors; and

(3) consideration of audited financial statements for the year ended December 31, 2009.

Items 1 and 2 require the approval of a simple majority of the shares voted on the matter. Item 3 will not involve a vote of the shareholders. The record date for the meeting is October 26, 2010. Tikcro will send its shareholders of record a proxy statement describing the various matters to be voted upon at the meeting, along with a proxy card enabling them to indicate their vote on each matter.

About Tikcro Technologies:

About Tikcro Technologies:

Tikcro has holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Biocancell's leading drug, BC-819, is a double stranded DNA plasmid construct that incorporates the gene for diphtheria toxin (DTA) under the regulation of the promoter sequence for H19 gene. Pursuant to U.S. FDA approved protocols, BioCancell isconducting the following clinical trials in Israel and in the U.S. using BC-819:

-Phase IIb clinical trial for the treatment of superficial bladder carcinoma cancer;

-Phase I/IIa clinical trial for the treatment of pancreatic cancer; and

-Phase I/IIa clinical trial for the treatment of ovarian cancer.

For more information, visit Tikcro website at [ www.tikcro.com ].


Publication Contributing Sources